<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01727895</url>
  </required_header>
  <id_info>
    <org_study_id>Betaglucan_immunity</org_study_id>
    <nct_id>NCT01727895</nct_id>
  </id_info>
  <brief_title>Effects of Orally Administered Beta-glucan on Leukocyte Function in Humans</brief_title>
  <acronym>BG</acronym>
  <official_title>Effects of Orally Administered Beta-glucan on Leukocyte Function in Humans, a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test wether orally administered Beta-glucan has systemic
      effects in humans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The immunostimulatory properties of mushrooms have been recognized for centuries, and
      &quot;medicinal&quot; mushrooms are still widely used in alternative medicine all over the world.
      Although a number of fungal components have been implicated in these properties, Beta-glucans
      have attracted the most attention. However, although Beta-glucans are widely used as a health
      food supplement, their immunomodulatory effects after administration in humans have not yet
      been determined.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor Necrosis Factor (TNF)-α Secretion by ex Vivo Lipopolysaccharide (LPS)-Stimulated Peripheral Blood Mononuclear Cells (PBMCs)</measure>
    <time_frame>up to 21 days</time_frame>
    <description>The primary objective of the study is to evaluate the systemic effects of orally administered Beta-glucan on innate immune responses of leukocytes. The effects of Beta-glucan will be determined by measuring the ex vivo responsiveness of leukocytes to various inflammatory stimuli as a surrogate marker of the antimicrobial response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Production of Other Cytokines (TNF-α, Interleukin (IL)-6, IL-10, IL-1β, IL-17, IL-22, Interferon (IFN)-γ) by Leukocytes ex Vivo Stimulated With Various Stimuli (Including LPS, Pam3Cys, Mycobacterium Tuberculosis, Poly(I:C), Candida, Staph Aureus)</measure>
    <time_frame>days 0, 6, 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• the Absorbance of Orally Administered Beta-glucan Into the Blood Compartment, Measured by ELISA</measure>
    <time_frame>Days 0, 6, 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Transcriptional Pathways (by Use of Microarrays) With Focus on Inflammatory Pathways.</measure>
    <time_frame>Days 0, 6, 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Changes in Phenotype and Gene Expression Caused by Mechanisms Other Than Changes in the Underlying DNA Sequence (Epigenetic Modifications)</measure>
    <time_frame>Days 0, 6, 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• the Leukocyte Capacity to Phagocytose and Kill the Fungal Pathogen Candida Albicans (Antifungal Activity).</measure>
    <time_frame>Days 0, 6, 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Composition of Faecal Microbiota</measure>
    <time_frame>Days 0, 6, 21</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Immunologic Deficiency Syndromes</condition>
  <arm_group>
    <arm_group_label>Beta-glucan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Commercial available Beta-glucan derived from bakers yeast (S. Cerevisiae): Glucan #300® produced by Transferpoint, Columbia, United States. 2 capsules of 500mg Glucan #300®, daily, for seven days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Beta-glucan (Glucan #300®)</intervention_name>
    <arm_group_label>Beta-glucan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Age ≥18

          -  Healthy males

        Exclusion Criteria:

          -  Subjects with a history of allergy or intolerance to Beta-glucan

          -  Use of any medication

          -  Participation in a drug trial or donation of blood 3 months prior to Beta-glucan
             administration

          -  Use of antibiotics, norit, laxatives (up till 6 months prior to inclusion),
             cholestyramine, acid burn inhibitors or immune suppressive agents (up till 3 months
             prior to inclusion), and pre- and probiotics (up till 1 month prior to inclusion).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mihai Netea, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University Nijmegen Medical Centre, The Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2012</study_first_submitted>
  <study_first_submitted_qc>November 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2012</study_first_posted>
  <results_first_submitted>July 1, 2014</results_first_submitted>
  <results_first_submitted_qc>July 1, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 31, 2014</results_first_posted>
  <last_update_submitted>July 1, 2014</last_update_submitted>
  <last_update_submitted_qc>July 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Betaglucan, immune modulation, immunoparalysis, immune suppression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment took place from April until May 2013 in the Radboud University Medical Centre Nijmegen.</recruitment_details>
      <pre_assignment_details>Exclusion of subjects was based on pre-defined exclusion criteria or the unability of subjects to comply with the study time schedule.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Beta-glucan</title>
          <description>Commercial available Beta-glucan derived from bakers yeast (S. Cerevisiae): Glucan #300® produced by Transferpoint, Columbia, United States. 2 capsules of 500mg Glucan #300®, daily, for seven days.
Beta-glucan (Glucan #300®)</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>No intervention</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Beta-glucan</title>
          <description>Commercial available Beta-glucan derived from bakers yeast (S. Cerevisiae): Glucan #300® produced by Transferpoint, Columbia, United States. 2 capsules of 500mg Glucan #300®, daily, for seven days.
Beta-glucan (Glucan #300®)</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>No intervention</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" lower_limit="19" upper_limit="22"/>
                    <measurement group_id="B2" value="20" lower_limit="19" upper_limit="24"/>
                    <measurement group_id="B3" value="20" lower_limit="19" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>TNF-α Secretion by ex Vivo LPS-Stimulated Peripheral Blood mononuclear cells</title>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="691" lower_limit="276" upper_limit="2649"/>
                    <measurement group_id="B2" value="749" lower_limit="287" upper_limit="1160"/>
                    <measurement group_id="B3" value="720" lower_limit="282" upper_limit="1905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tumor Necrosis Factor (TNF)-α Secretion by ex Vivo Lipopolysaccharide (LPS)-Stimulated Peripheral Blood Mononuclear Cells (PBMCs)</title>
        <description>The primary objective of the study is to evaluate the systemic effects of orally administered Beta-glucan on innate immune responses of leukocytes. The effects of Beta-glucan will be determined by measuring the ex vivo responsiveness of leukocytes to various inflammatory stimuli as a surrogate marker of the antimicrobial response</description>
        <time_frame>up to 21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Beta-glucan</title>
            <description>Commercial available Beta-glucan derived from bakers yeast (S. Cerevisiae): Glucan #300® produced by Transferpoint, Columbia, United States. 2 capsules of 500mg Glucan #300®, daily, for seven days.
Beta-glucan (Glucan #300®)</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Necrosis Factor (TNF)-α Secretion by ex Vivo Lipopolysaccharide (LPS)-Stimulated Peripheral Blood Mononuclear Cells (PBMCs)</title>
          <description>The primary objective of the study is to evaluate the systemic effects of orally administered Beta-glucan on innate immune responses of leukocytes. The effects of Beta-glucan will be determined by measuring the ex vivo responsiveness of leukocytes to various inflammatory stimuli as a surrogate marker of the antimicrobial response</description>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="691" lower_limit="276" upper_limit="2649"/>
                    <measurement group_id="O2" value="749" lower_limit="287" upper_limit="1160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>• Production of Other Cytokines (TNF-α, Interleukin (IL)-6, IL-10, IL-1β, IL-17, IL-22, Interferon (IFN)-γ) by Leukocytes ex Vivo Stimulated With Various Stimuli (Including LPS, Pam3Cys, Mycobacterium Tuberculosis, Poly(I:C), Candida, Staph Aureus)</title>
        <time_frame>days 0, 6, 21</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>• the Absorbance of Orally Administered Beta-glucan Into the Blood Compartment, Measured by ELISA</title>
        <time_frame>Days 0, 6, 21</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>• Transcriptional Pathways (by Use of Microarrays) With Focus on Inflammatory Pathways.</title>
        <time_frame>Days 0, 6, 21</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>• Changes in Phenotype and Gene Expression Caused by Mechanisms Other Than Changes in the Underlying DNA Sequence (Epigenetic Modifications)</title>
        <time_frame>Days 0, 6, 21</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>• the Leukocyte Capacity to Phagocytose and Kill the Fungal Pathogen Candida Albicans (Antifungal Activity).</title>
        <time_frame>Days 0, 6, 21</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Composition of Faecal Microbiota</title>
        <time_frame>Days 0, 6, 21</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Beta-glucan</title>
          <description>Commercial available Beta-glucan derived from bakers yeast (S. Cerevisiae): Glucan #300® produced by Transferpoint, Columbia, United States. 2 capsules of 500mg Glucan #300®, daily, for seven days.
Beta-glucan (Glucan #300®)</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>No intervention</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flare of acne, one week after discontinuation of Beta-glucan intake</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Drs. Jenneke Leentjens</name_or_title>
      <organization>Radboud UMC</organization>
      <phone>0031-243668420</phone>
      <email>Jenneke.Leentjens@radboudumc.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

